Abstract
IntroductionPatients with relapsed or refractory malignancies have a poor prognosis. Immunotherapy with chimeric antigen receptor T (CAR-T) cells redirects a patient’s immune cells against the tumour antigen. CAR-T cell therapy...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have